Investor Presentaiton
COMPANY OVERVIEW
Pioneering rare cannabinoid production
Parallel is a leader in production and commercialization of rare cannabinoids, and we are well-positioned to market and partner on both
OTC and pharma products
There are more than 110 cannabinoids in the cannabis plant with significant therapeutic potential...
1
CBC
Pain reduction, anti-inflammatory,
antibiotic, antifungal, and
anticancer
CBG
Antidepressant, a muscle relaxant,
antibiotic and antifungal agent, and
blood pressure reducer
Social Consumption Markets:
Medical & Recreational
Cannabis
Consumer Packaged Goods:
Beauty and Personal Care
Health & Wellness Products
⭑U
Near Term Value
$190B2
Creation
10
$490B³
$250B
3
THC-V
Appetite-suppressant
and antiseizure
CBN
Useful for aiding sleep, reducing
pain, and reducing muscle spasms
Health & Pharmaceuticals:
Innovative IP & New Drug
Development
4
$850B
匙
Long Term Value
Creation
1. Currently more than 113 cannabinoids have been isolated in the cannabis plant with potentially therapeutic value of the newly researched "exotic" molecules. 2. Represents 2020E market value based on BofAML Global Research. 3. Represents 2018A market
sizes based on Euromonitor, Jefferies. 4. Represents 2019E Global prescription drug sales based on EvaluatePharma, World Preview Report, August 2017. Source: Company filings, Cantor Fitzgerald Equity Research.
37
שייView entire presentation